Massachusetts General Hospital: Osteoporosis, Postmenopausal trials
The registry lists 11 Osteoporosis, Postmenopausal studies with Massachusetts General Hospital as lead sponsor. 3 are open to participants now and 4 have results posted.
Phase 2 1Phase 3 1Phase 4 8No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Romosozumab and Denosumab Combination Therapy for OsteoporosisNot yet recruitingNCT07909304Phase 4
- Combined Anabolic TherapyRecruitingNCT06558188Phase 4
- Mechanisms of Anabolic Osteoporosis TherapyRecruitingNCT05688969Not applicable
- Bone Modeling Effects of Combined Anabolic/Antiresorptive AdministrationCompletedNCT04026256Phase 4Results posted
- Denosumab and Teriparatide Study (DATA-HD and DATA-EX)CompletedNCT02176382Phase 4Results posted
- Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone ResorptionCompletedNCT01750086Phase 4Results posted
- Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal WomenCompletedNCT00086619Phase 2Results posted
- Anabolic Therapy in Postmenopausal OsteoporosisActive, not recruitingNCT05010590Phase 4
- Comparative Antiresorptive Efficacy Discontinuation of DenosumabActive, not recruitingNCT03623633Phase 4
- Effect of Mechanical Loading With PTH on Cortical BoneWithdrawnNCT03232476Phase 4
- Effects of Parathyroid Hormone in Men With OsteoporosisCompletedNCT00000427Phase 3